Career history of Takao Iwayanagi
Former positions of Takao Iwayanagi
| Companies | Position | Start | End |
|---|---|---|---|
| University of Tokyo | Corporate Officer/Principal | 01/01/1992 | 01/01/1993 |
| HITACHI, LTD. | Chief Tech/Sci/R&D Officer | - | - |
| Tokyo Institute of Technology | Corporate Officer/Principal | 01/01/1997 | - |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Director/Board Member | - | - |
Training of Takao Iwayanagi
| University of Tokyo | Doctorate Degree |
Statistics
International
| Japan | 4 |
| United States | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Producer Manufacturing | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| HITACHI, LTD. | Producer Manufacturing |
| Private companies | 1 |
|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
- Stock Market
- Insiders
- Takao Iwayanagi
- Experience
